Antidepressive Agents

"Antidepressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

Descriptor ID	D000928
MeSH Number(s)	D27.505.954.427.700.122
Concept/Terms	Antidepressive Agents Antidepressive Agents Agents, Antidepressive Antidepressant Drugs Drugs, Antidepressant Antidepressants Thymoanaleptics Thymoanaleptics Thymoleptics Thymoleptics

Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Psychotropic Drugs [D27.505.954.427.700]
Antidepressive Agents [D27.505.954.427.700.122]

Below are MeSH descriptors whose meaning is related to "Antidepressive Agents".

Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents".

Antidepressive Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents, Tricyclic

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antidepressive Agents" by people in this website by year, and whether "Antidepressive Agents" was a major or minor topic of these publications.

Bar chart showing 183 publications over 30 distinct years, with a maximum of 14 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	1	3
1997	5	0	5
1998	3	0	3
1999	0	3	3
2000	2	1	3
2002	4	0	4
2003	3	1	4
2004	6	2	8
2005	3	3	6
2006	3	5	8
2007	6	1	7
2008	4	1	5
2009	2	4	6
2010	7	3	10
2011	7	3	10
2012	7	4	11
2013	10	4	14
2014	5	1	6
2015	6	3	9
2016	4	1	5
2017	8	2	10
2018	6	3	9
2019	3	4	7
2020	4	4	8
2021	1	1	2
2022	0	5	5
2023	0	1	1
2024	2	5	7
2025	3	0	3
2026	1	0	1

Below are the most recent publications written about "Antidepressive Agents" by people in Profiles.

Bendel RA, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Bingham KS. Effect of continuation treatment on health-related quality of life in remitted psychotic depression. J Affect Disord. 2026 Oct 15; 411:122015.

View in: PubMed
Deligiannidis KM, Meltzer-Brody S. Neurosteroid treatment of postpartum depression and beyond. Br J Psychiatry. 2025 Jun; 226(6):340-342.

View in: PubMed
Julce C, Flahive J, Lightbourne T, Podila S, Mahanna A, Zimmermann M, Sheldrick RC, Moore Simas TA, Byatt N. Descriptive Characteristics of Psychiatric Medication Discontinuation Among Perinatal Women With Depressive Symptoms. Early Interv Psychiatry. 2025 Jun; 19(6):e70070.

View in: PubMed
Butterfield NN, Luzon Rosenblut C, Fava M, Correll CU, Rothschild AJ, Murrough JW, Mathew SJ, Beatch GN, Grayson C, Harden C, Qian J, McIntosh J, Namdari R, Kenney C. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 05 01; 8(5):e2514278.

View in: PubMed
Carter E, Banerjee S, Alexopoulos GS, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ. Prediction of remission of pharmacologically treated psychotic depression: A machine learning approach. J Affect Disord. 2025 Jul 15; 381:291-297.

View in: PubMed
Jeung C, Attanasio LB, Geissler KH. Improving perinatal depression screening uptake: The impact of Medicaid reimbursement policy in Massachusetts. Health Serv Res. 2025 Apr; 60 Suppl 2:e14420.

View in: PubMed
Ihaddadene RA, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Bingham KS. Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trial. Psychiatry Res. 2024 Dec; 342:116192.

View in: PubMed
Rothschild AJ. Question: How Should I Switch From One Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to Another SSRI or SNRI in a Patient With Major Depressive Disorder? J Clin Psychopharmacol. 2024 Sep-Oct 01; 44(5):531-532.

View in: PubMed
Andrews P, Vega JN, Szymkowicz SM, Newhouse P, Tyndale R, Elson D, Kang H, Siddiqi S, Tyner EB, Mather K, Gunning FM, Taylor WD. Effects of open-label transdermal nicotine antidepressant augmentation on affective symptoms and executive function in late-life depression. J Affect Disord. 2024 Oct 01; 362:416-424.

View in: PubMed
Cintr?n Pastrana MA, Irizarry Flores JC, Rothschild AJ. Challenges in the Treatment of Psychotic Bipolar Depression. J Clin Psychopharmacol. 2024 Jul-Aug 01; 44(4):407-412.

View in: PubMed

People

Explore

Similar Concepts

Top Journals